Cargando…

Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience

PURPOSE: Ablative treatment of oligometastases has shown survival benefit with certain tumors, although these effects still are to be demonstrated in prostate cancer. MATERIALS AND METHODS: We analysed the toxicity and clinical control results obtained in patients with bone-only oligometastatic pros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Iglesias, Ángel L., Morillo-Macías, Virginia, Santafé-Jiménez, Ana, Ferrer-Albiach, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Radiation Oncology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535412/ https://www.ncbi.nlm.nih.gov/pubmed/36200308 http://dx.doi.org/10.3857/roj.2022.00101

Ejemplares similares

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer
por: Mercier, Carole, et al.
Publicado: (2022)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
por: Hasan, Hamza, et al.
Publicado: (2020)

SABR in oligometastatic breast cancer: Current status and future directions
por: Stewart, Rachel, et al.
Publicado: (2021)

Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
por: Beato Tortajada, Inmaculada, et al.
Publicado: (2021)

Prostate Region-Wise Imaging Biomarker Profiles for Risk Stratification and Biochemical Recurrence Prediction
por: Sánchez Iglesias, Ángel, et al.
Publicado: (2023)

The Usefulness of Adaptative Radiotherapy in Prostate Cancer: How, When, and Who?
por: Muelas-Soria, Rodrigo, et al.
Publicado: (2022)

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac
por: Janssen, Tomas M., et al.
Publicado: (2022)

The Impact of Frailty Screening on Radiation Treatment Modification
por: Fernández-Camacho, Encarnación, et al.
Publicado: (2022)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Oligometastatic Prostate Cancer to the Navicular Bone: Case Report
por: Reyes, Diane K., et al.
Publicado: (2015)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Implementation of an intraoperative electron radiotherapy in vivo dosimetry program
por: López-Tarjuelo, Juan, et al.
Publicado: (2016)

Sabre tibia in Paget’s disease of bone
por: Clark, Kristina E N, et al.
Publicado: (2023)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
por: Rogowski, Paul, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
por: Dhaliwal, Inderdeep, et al.
Publicado: (2022)

Role of surgery in oligometastatic prostate cancer
por: Jenjitranant, Pocharapong, et al.
Publicado: (2019)

Brachytherapy for oligometastatic prostate cancer to the penis
por: Martz, Nicolas, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
por: Palma, David A., et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
por: Olson, Robert, et al.
Publicado: (2020)

Quantification of hyperpolarisation efficiency in SABRE and SABRE-Relay enhanced NMR spectroscopy
por: Richardson, Peter M., et al.
Publicado: (2018)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Oligometastatic prostate cancer: Reality or figment of imagination?
por: Foster, Corey C., et al.
Publicado: (2018)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Oligometastatic carcinoma prostate – An overview of the last decade
por: Shah, Milap J, et al.
Publicado: (2023)

Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer
por: Filippini Velázquez, G., et al.
Publicado: (2022)

SABRE : sistema de reservaciones para agencias de viajes
por: Mata Hernández, Elizabeth
Publicado: (1999)

Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy
por: Maranzano, Ernesto, et al.
Publicado: (2021)

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer
por: Miura, Yuji, et al.
Publicado: (2019)

Radiotherapy of oligometastatic prostate cancer: a systematic review
por: Rogowski, Paul, et al.
Publicado: (2021)

Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?
por: Supiot, Stéphane, et al.
Publicado: (2019)

The current role of precision surgery in oligometastatic prostate cancer
por: von Deimling, M., et al.
Publicado: (2022)

SABRE: a system for the assessment of body radioactivity ; 2, main features of SABRE 3
por: Venn, J B
Publicado: (1978)

Pneumomediastinum as a complication of SABR for lung metastases
por: Rodríguez-Ruiz, María Esperanza, et al.
Publicado: (2015)

Sistema de reservaciones SABRE /
por: Ramírez Juárez, Magdalena
Publicado: (2000)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2d2nomefa6jcf1ftceb02u05t4